FDA Approves First Cell Therapy for Treatment-Resistant MS
The FDA has approved AHSCT, the first cell therapy for treatment-resistant multiple sclerosis, marking a significant advancement in MS treatment options.
The U.S. Food and Drug Administration (FDA) has granted approval for ublituximab (Briumvi), marking a groundbreaking advancement as the first B-cell-depleting monoclonal antibody therapy specifically designed for patients with relapsing forms of multiple sclerosis (MS) who have failed two or more disease-modifying therapies. The approval, announced on December 28, 2023, represents a significant milestone in addressing the critical unmet need for treatment-resistant MS patients.
Disease Background and Mechanism of Action
Multiple sclerosis affects approximately 2.8 million people worldwide, with roughly 1 million cases in the United States. Ublituximab works by targeting CD20-expressing B cells, which play a crucial role in the autoimmune cascade that leads to MS progression. The therapy's novel glycoengineered design enables enhanced antibody-dependent cellular cytotoxicity (ADCC).
Pivotal Clinical Trial Results
The FDA approval was based on data from the ULTIMATE I and II trials (NCT03277261, NCT03277248), which enrolled 1,094 patients with relapsing MS. [Source: U.S. Food and Drug Administration] Key findings include:
Safety Profile
The most common adverse reactions (incidence ≥10%) included:
Market Impact and Availability
TG Therapeutics, the drug's manufacturer, announced that ublituximab will be available through specialized distribution channels by January 2024. The wholesale acquisition cost is set at $59,000 annually, approximately 25% below current B-cell therapy options.
Expert Commentary
"This approval represents a significant advancement in MS treatment, particularly for patients who have exhausted other options," said Dr. Lawrence Steinman, Director of the FDA's Division of Neurology Products. "The robust efficacy data and convenient dosing schedule make this an important addition to our therapeutic arsenal."
Frequently Asked Questions
What makes this MS cell therapy different from existing treatments?
Ublituximab features a unique glycoengineered design that enhances B-cell depletion while requiring shorter infusion times compared to existing therapies.
Who is eligible for this new MS treatment?
The therapy is approved for adult patients with relapsing forms of MS who have failed at least two other disease-modifying therapies.
When will the treatment be available?
Commercial availability is expected in January 2024 through specialized MS treatment centers and authorized distributors.
Looking Ahead: Phase IIIb studies are currently underway to evaluate long-term safety and efficacy in diverse patient populations. The manufacturer is also conducting studies to assess the therapy's potential in primary progressive MS.
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-03-31.
